These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36915205)

  • 1. Can a 3 months treatment with oral Desogestrel prior to insertion of the etonogestrel-releasing contraceptive implant improve continuation rate at 1 year? A randomized trial.
    Lombardi Fäh V; Catarino R; Castillo S; Badda M; Gezer-Dickschat S; Thieringer F; Tschudin S; Viviano M; Yaron M
    BMC Res Notes; 2023 Mar; 16(1):35. PubMed ID: 36915205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial.
    Vieira CS; de Nadai MN; de Melo Pereira do Carmo LS; Braga GC; Infante BF; Stifani BM; Ferriani RA; Quintana SM
    Contraception; 2019 Oct; 100(4):258-263. PubMed ID: 31145885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
    Bahamondes L; Brache V; Ali M; Habib N;
    Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.
    Carvalho N; Margatho D; Cursino K; Benetti-Pinto CL; Bahamondes L
    Fertil Steril; 2018 Nov; 110(6):1129-1136. PubMed ID: 30396557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
    Short M; Dallay D; Omokanye S; Hanisch JU; Inki P
    Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):79-88. PubMed ID: 22200172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and continuation rates of the etonogestrel-subdermal contraceptive implant versus short-acting contraceptive methods offered at no cost in Campinas, Brazil.
    Laporte M; Marcelino AC; da Cunha Pereira P; Espejo-Arce X; Juliato CT; Bahamondes L
    Int J Gynaecol Obstet; 2024 Jul; 166(1):305-311. PubMed ID: 38328989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
    Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
    Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability of long-acting, progestin-only contraception in Europe: a two-year prospective, non-interventional study.
    Short M; Dallay D; Omokanye S; Stauch K; Inki P
    Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):29-38. PubMed ID: 24289528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ENG-releasing subdermal implants in postpartum teenagers - an open-label trial study protocol.
    Barbieri MM; Juliato CRT; Bahamondes L; Surita FG
    Reprod Health; 2020 Jun; 17(1):100. PubMed ID: 32576199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence and x-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: a 3-year, randomized, double-blind study.
    Schnabel P; Merki-Feld GS; Malvy A; Duijkers I; Mommers E; van den Heuvel MW
    Clin Drug Investig; 2012 Jun; 32(6):413-22. PubMed ID: 22540269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
    Clure C; Sheeder J; Lazorwitz A
    Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake, discontinuation, and continuation rate of long-acting contraceptive methods when offered at no cost in Campinas, Brazil.
    Laporte M; Marcelino AC; Pereira PDC; Espejo-Arce X; Juliato CT; Bahamondes L
    Contraception; 2024 Apr; 132():110363. PubMed ID: 38195047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between BMI and continuity of etonogestrel (ENG)-releasing implant.
    Mohr-Sasson A; Dalal L; Bhalwal A
    Int J Gynaecol Obstet; 2024 Oct; 167(1):254-258. PubMed ID: 38712353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of Breastfeeding Exclusivity and Duration Rates Between Immediate Postpartum Levonorgestrel Versus Etonogestrel Implant Users: A Prospective Cohort Study.
    Krashin JW; Lemani C; Nkambule J; Talama G; Chinula L; Flax VL; Stuebe AM; Tang JH
    Breastfeed Med; 2019; 14(1):69-76. PubMed ID: 30508390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting.
    Berlan E; Mizraji K; Bonny AE
    Contraception; 2016 Jul; 94(1):81-6. PubMed ID: 26948183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.
    Timmer CJ; Mulders TM
    Clin Pharmacokinet; 2000 Sep; 39(3):233-42. PubMed ID: 11020137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.